Subcutaneous, intravenous lecanemab outcomes similar

Outcomes following subcutaneous and intravenous treatment with lecanemab for Alzheimer’s disease were comparable, according to a group of abstracts presented at the Alzheimer’s Association International Conference.
Intravenous lecanemab (Leqembi, Eisai) has yielded substantial reductions in amyloids and significantly slower clinical decline, Michael Irizarry, MD, MPH, senior vice president, clinical research, and deputy chief clinical officer at Eisai, and colleagues wrote.
The FDA also has approved a subcutaneous 360 mg maintenance dose and is considering a subcutaneous 500 mg initiation dose,

Former soccer players show evidence of cognitive changes

Former elite level soccer players had higher levels of depression and anxiety, and subjective difficulties with thinking and decision-making, according to a study presented at the Alzheimer’s Association International Conference 2026.
The study by Caleigh Grace Lynch, MSc, research technician at Imperial College London, and colleagues compared the brain health and self-reported neurological symptoms of the players with a control group composed of people who did not have a history of repetitive head injuries. It was the first and largest study of its kind to feature former soccer players,

Body’s own cell-to-cell messaging packets studied as the basis for next-generation medicines

The Blood and Tissue Bank is studying how to therapeutically manufacture and use a type of nanoparticles released by the body's cells to communicate with one another, in one of the most promising fields of research for the therapies of the future. New medicines and advanced therapies modify cells (immune cells), genes and tissues to treat diseases such as cancer. However, the next step is to focus on these subcellular packages loaded with biological information, known as extracellular vesicles (EVs), which perform essential functions such as tissue regeneration and the modulation of inflammation.

What to know about menopause: Latest guidance to empower women

Menopause. Suddenly, the topic is everywhere in the headlines, in our news feeds, on podcasts. Until recently, this normal life stage marking the end of a woman's reproductive years was discussed only in certain circles, limiting knowledge and research. Occurring in middle-aged women, the transition can cause more than 4 out of 5 to suffer debilitating symptoms that can significantly affect their lives.

Inhibiting protein to treat myeloproliferative neoplasms shows preclinical promise

Inhibiting menin, a protein that supports leukemia growth and is already targeted to treat some forms of leukemia, also holds promise for treating myeloproliferative neoplasms. A new study from scientists at St. Jude Children's Research Hospital showed that inhibiting menin significantly extended survival and reversed multiple disease features in preclinical models. The findings were published today in Cancer Cell.

Night owls eat later, choose less nutritious food, carry more belly fat and show higher metabolic risk

For generations, early to bed and early to rise was seen as the blueprint for a healthy life, and any departure from it was often considered unhealthy. Scientists, however, have discovered that whether someone is an early bird who wakes up early and starts the day with energy or a night owl who naturally stays up late and wakes up later is far more than a lifestyle choice. This pattern reflects the body's natural preference for the timing of sleep and wake cycles within a 24-hour day.

Scientists improve the analgesic efficacy of morphine

Scientists at the Department of Cell Biology of the University of Malaga have taken a step forward in the search for more effective treatments for pain with a new study that advances efforts to mitigate the addictive effects of morphine—one of the main drugs used for this purpose—as well as the development of analgesic tolerance to the drug. Specifically, they identified that activation of a dopamine receptor, D4, enhances morphine's analgesic effect and prevents the development of tolerance to morphine. The results of the study were published in The Journal of Pain.